ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
ABIVAX

BRIEF

published on 11/19/2025 at 18:05, 15 days 10 hours ago

ABIVAX: Information on share capital and voting rights as of October 31, 2025

Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF

published on 11/19/2025 at 18:05, 15 days 10 hours ago

ABIVAX: Share and voting rights balance sheet as of October 31, 2025

Share Capital Voting Rights Biotechnology Actions Abivax
BRIEF

published on 11/03/2025 at 22:10, 1 month 1 day ago

Abivax reveals promising results for Obefazimod in the treatment of ulcerative colitis

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials Clinical Results
PRESS RELEASE

published on 11/03/2025 at 22:05, 1 month 1 day ago

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Abivax announces significant improvements in quality of life for patients with ulcerative colitis in Phase 3 ABTECT induction trials of Obefazimod, incorporating patient-reported outcomes data

Abivax Obefazimod Ulcerative Colitis Phase 3 Patient-reported Outcomes
BRIEF

published on 10/24/2025 at 09:41, 1 month 11 days ago

JP Morgan Chase & Co. Crosses the 5% Threshold at ABIVAX

Voting Rights Capital Abivax Crossing Thresholds JP Morgan
BRIEF

published on 10/15/2025 at 18:05, 1 month 20 days ago

ABIVAX: Status of shares and voting rights as of September 30, 2025

Share Capital Voting Rights Biotechnology Euronext Abivax
BRIEF

published on 10/13/2025 at 14:50, 1 month 22 days ago

JP Morgan exceeds the 5% threshold at ABIVAX

Voting Rights Actions Abivax Threshold Crossing JP Morgan
BRIEF

published on 10/06/2025 at 10:05, 1 month 29 days ago

Abivax Unveils Promising New Results from Obefazimod

Abivax Obefazimod Ulcerative Colitis Clinical Trial Results
PRESS RELEASE

published on 10/06/2025 at 10:00, 1 month 29 days ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
Abivax announces late-breaking presentation at UEG Meeting on ABTECT Induction Trial results in patients with and without prior inadequate response to advanced therapies. Obefazimod shows clinically meaningful improvements and favorable safety profile

Abivax Obefazimod Ulcerative Colitis Clinical Trial Late-breaking Presentation
BRIEF

published on 10/05/2025 at 17:05, 1 month 30 days ago

Abivax Presents Promising 8-Week ABTECT Trial Results

Abivax Obefazimod Ulcerative Colitis Clinical Trials Safety Data

Accesswire

Published on 12/05/2025 at 02:35, 1 hour 57 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 2 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 3 hours 32 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 5 hours 27 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 5 hours 32 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 2 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 4 hours 41 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 7 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 8 hours 17 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 9 hours 22 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 10 hours 32 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 10 hours 47 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 10 hours 48 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 21 hours 31 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 10 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE